|  |  |
| --- | --- |
| **MEETING SUBJECT:** | **PINTAD 2017 “August” Teleconference** |
| **DATE / TIME:** | **8 September 17 / 11:00 AM EST** |
| **PREPARED BY:** | **Annette Schmid/ Paul Galette** |
| **LOCATION:** | **Teleconference** |

**MEETING SUMMARY**

DISCUSSION POINTS:

|  |  |
| --- | --- |
| **1** | **Welcome** |
| **2** | **Paul Galette**, Scientific Leader GSK present and led a discussion on ***“What quality does pharma expect in multi center FDG-PET studies?”-*** a presentation that was developed in collaboration with **Dr Neel Patel**, Consultant Radionuclide Radiologist and Experimental Medicine Imaging Physician  The full slide deck is available for download.  It ensued a lively discussion on whether the community was using the PERCIST criteria in their ongoing clinical trials. Jayant Narang shared that there was one trial that was about to start that is currently considering implementing PERCIST in PAREXEL Imaging’s portfolio. Neither GNE, nor Takeda nor GSK are currently actively running PERCIST trials.  Eric Perlman asked whether the community was using the QIBA profiles for their imaging/ clinical trials. GSK and Takeda mentioned they like using the profiles for reference.  The ongoing challenge was raised on how to implement a change in the QC efforts, whether from sponsor side, imaging vendor side or the sites. Paul Galette highlighted the importance of having a direct line of communication with the imaging sites- which found general agreement. Sponsor commitment and imaging vendor support were also identified as critical. Annette Schmid encouraged the group to participate at the next meeting that will discuss site accreditation programs.  It was determined that it may be beneficial to have a direct link to the QIBA profiles on the PINTAD website. Annette Schmid will explore the best approach in discussion with QIBA leaders. |
| **3** | **Next meeting**  **Friday, 29Sept17 11:00 am ET** |